- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
Two major effects of stem cell therapy bring hope to patients with renal fibrosis
Two major effects of stem cell therapy bring hope to patients with renal fibrosis. Renal fibrosis is the common pathological outcome of the progression of various chronic kidney diseases.
Introduction: In the field of prevention and treatment of organ fibrosis, stem cell therapy uses paracrine to exert its anti-inflammatory, anti-fibrotic and angiogenic effects. At present, stem cell therapy has been developed as a new drug for clinical treatment of liver fibrosis and skin fibrosis. the study. Stem cell therapy can also prevent and treat renal fibrosis, which has important clinical application value.
Renal fibrosis is the common pathological outcome of the progression of various chronic kidney diseases, a key factor that accelerates the progression of the disease, and an important factor affecting the prognosis of kidney transplantation. The pathological manifestations are glomerular sclerosis, renal tubular atrophy, fibroblasts and inflammatory cells. The accumulation of calcium and the loss of peritubular capillaries lead to a decline in renal function.
Stem Cell Therapy
Previous studies have shown that the occurrence and development of renal fibrosis is related to hypoxia, inflammatory response, renal cell damage and the participation of pro-fibrosis factors. However, the current stage of prevention and treatment is limited, resulting in the progress of renal fibrosis in many patients that require renal dialysis or Kidney transplantation stage. The 2 major effects of stem cell therapy bring new hope to patients with renal fibrosis!
1. Stem cell therapy relieves kidney inflammation
Stem cells in the body can direct the migration of damaged kidney tissues and chronic inflammation sites, regulate immune function, inhibit inflammatory factors, and reduce inflammation.
Furuichi et al. injected the treated adipose-derived mesenchymal stem cells into a mouse model of acute kidney injury through the tail vein, and found that the necrosis of renal tubular epithelial cells and the degree of infiltration of interstitial inflammatory cells were reduced, and the expression of inflammatory factors and chemokines Decrease, it was found that the model mice had no renal fibrosis.
2. Stem cell therapy repairs renal fibrosis
Stem cells homing to the kidney secrete various factors to repair damaged epithelial cells and promote the differentiation of internal stem cells. On the other hand, stem cell therapy activates the function of inhibiting the excessive production and deposition of extracellular matrix.
Studies have confirmed that stem cell therapy can effectively alleviate the kidney damage induced by aristolochic acid, which may inhibit the expression of TGF-β/Smad signaling pathway and inhibit the process of renal cell epithelial to mesenchymal transition, which makes mouse kidney fibrin The deposition is significantly reduced, the blood creatinine and urea nitrogen levels decrease, and the kidney function is improved.
Zhang et al. implemented stem cell therapy on chronic cyclosporine rats and found that the blood creatinine and urea nitrogen levels of rats were significantly improved, and the degree of interstitial fibrosis was also lower than that of the model group, indicating that stem cell therapy can reduce histological damage and renal damage The function is obviously improved.
Clinical case of stem cell therapy for renal fibrosis
Reinders et al. conducted a safety and feasibility study on stem cell therapy for renal fibrosis. The researchers selected 6 patients with renal fibrosis who received stem cell therapy infusions. The infusions were well tolerated. Clinical and immunological monitoring were performed within 24 weeks after the injection. No related serious adverse events were reported.
(sourceinternet, reference only)